Lonza Acquires Merck KGaA CDMO Business for Millions
Lonza agreed to acquire the contract development and manufacturing organization business of Merck KGaA, Darmstadt, Germany, for a mid-triple-digit million-euro amount.
Merck KGaA, Darmstadt, Germany signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business to Lonza for a mid-triple-digit million-euro amount. The transaction aims to sharpen the focus of Merck's Life Science sector on innovation-driven businesses while providing the CDMO unit with a dedicated growth platform.
The deal includes several United States operations located in Carlsbad, California; Madison and Verona, Wisconsin; Indianapolis, Indiana; and bioconjugation sites in St. Louis, Missouri. BioReliance Contract Testing Services is excluded from the sale and will remain under Merck's ownership.
Lonza intends to use the acquisition to expand its manufacturing capacity and capabilities within the United States. The transaction is expected to close in mid-2027, pending regulatory approvals.
